Hansoh Pharmaceutical Group Company Limited 翰森製藥集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：3692） (1)委任獨立非執行董事； (2)董事委員會組成變動；及 (3)變更聯席公司秘書、授權代表及法律程序文件代理人 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 1 嚴先生已根據香港聯合交易所有限公司證券上市規則（「上市規則」）第3.09D條取 得法律意見，並確認了解其作為本公司董事的責任。本公司已接獲嚴先生根據 上市規則第3.13條作出的獨立性書面確認。本公司提名委員會已參照上市規則第 3.13條所載之獨立性標準評估及審核嚴先生的獨立性。董事會亦不知悉任何或會 影響嚴先生作出獨立判斷之情況，並信納彼具備履行獨立非執行董事職務所需之 品格、誠信、獨立性及經驗，且相信彼將能夠就本集團事務維持獨立觀點。董事 會認為彼為獨立人士。董事會認為，嚴先生將在公司治理、法律和合規風險防範 方面提供專業 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 翰森製藥集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：3692） 自願公告 與恒瑞醫藥訂立許可協議 翰森製藥集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事（「董 事」）會（「董事會」）欣然宣佈，於二零二五年十二月二十六日，本公司與江蘇恒瑞 醫藥股份有限公司（「許可人」）訂立許可協議（「許可協議」）。 根據許可協議，本公司獲得許可人的獨家許可，以於中國（不含香港、澳門及台 灣）開發、生產和商業化SHR6508（「該產品」），並有權根據許可協議條款進一步 分許可。本公司將向許可人支付三千萬元人民幣首付款，最高一點九億元人民幣 的潛在監管及商業里程碑付款，以及未來潛在產品淨銷售額的單位數百分比分級 特許權使用費。 該產品是一種鈣敏感受體(CaSR)變構調節劑，可提高受體對細胞外鈣的敏感性， 從而減少甲狀旁腺激素(PTH)的分泌。該產品目前處於III期臨床試驗階段，擬用 於治療需接受 ...

恒瑞医药公告，公司子公司成都盛迪医药有限公司与江苏豪森药业集团有限公司签署《商业化服务框架 协议》，委托豪森药业为公司帕立骨化醇软胶囊产品提供非独家商业化服务。 ...

Investment Rating - The report suggests a positive investment outlook for the medical device sector, particularly in brain-computer interface devices, which are expected to see accelerated commercialization due to supportive policies [1][3]. Core Insights - Recent policies have significantly increased support for innovation in medical devices, with the National Medical Products Administration actively promoting faster market entry for brain-computer interface devices, indicating a diverse application landscape and substantial future potential [1][3]. - The pharmaceutical sector is witnessing positive developments, such as GSK's approval of mepolizumab for a new indication in COPD patients, marking it as the first monthly administered biologic in China, which is expected to reduce the annual incidence of severe exacerbations significantly [1][32]. - The report highlights the approval of Wegovy® tablets in the U.S. for weight management, emphasizing its potential impact on the market as the first oral GLP-1 receptor agonist for this purpose [37][40]. Summary by Sections Pharmaceutical Sector - Mepolizumab has been approved for COPD treatment in China, with a monthly dosing schedule, targeting a significant patient population [1][32]. - The A/H share innovation drug sector maintains high activity levels, with new drug approvals and cross-border transactions remaining robust [16][28]. Biologics - Wegovy® tablets have been approved in the U.S. for weight management, showing similar weight loss efficacy to its injectable counterpart, with a significant portion of participants achieving substantial weight loss [37][40]. CXO and Pharmaceutical Supply Chain - The CXO sector continues to show upward momentum, supported by a stable order backlog, with November financing levels slightly above the annual average [44][46]. Medical Devices - The centralized procurement process for high-value medical consumables is progressing steadily, with high selection rates in multiple rounds of bidding, indicating a favorable environment for leading domestic companies [2][52]. Retail Pharmacy - The industry is undergoing a consolidation phase, with leading companies expected to benefit from increased market share through mergers and acquisitions [2][3]. Medical Services and Consumer Healthcare - Aier Eye Hospital's acquisition of 39 institutions for 960 million yuan strengthens its market position, with the acquired entities showing signs of financial recovery [2][3].

Core Viewpoint - The Chinese innovative pharmaceutical industry is experiencing a surge in business development (BD) transactions, but the secondary market's reaction has been mixed, with many companies seeing stock price declines despite positive announcements [2][6][10]. Group 1: Recent BD Transactions - Numerous BD transactions have been announced recently, including partnerships between Jiangsu Zaiming and Ipsen, and between Akeso and AstraZeneca, among others [2]. - In 2023, over 100 license-out transactions were completed in China, totaling more than $110 billion [4]. - As of December 21, 2025, there have been 15 transactions with upfront payments exceeding $100 million, and 37 transactions with total amounts over $1 billion, ranking second only to the U.S. [5]. Group 2: Market Reactions - Following the announcement of BD transactions, stock prices have shown varied responses; for instance, Akeso's stock fell by 13.58% on December 22, while Qianxin Bio's stock rose by 1.44% on the same day [3][6]. - A total of 37 BD transactions in A-shares and Hong Kong stocks this year resulted in 21 instances of stock price increases and 15 instances of declines on the first trading day after the announcements [6]. - The overall sentiment in the market has shifted from enthusiasm to a more rational approach, with stock prices reflecting this change [8][10]. Group 3: Industry Insights - Industry experts suggest that the complexity and long-term nature of innovative drug development require a rational approach from both capital and product markets [6][10]. - The current trend indicates that many Chinese pharmaceutical companies are still reliant on the "borrowed boat" strategy for international expansion, with a focus on licensing out rather than direct commercialization [12][13]. - The choice of out-licensing models varies, with smaller companies typically opting for complete licensing, while larger firms are exploring co-development models to retain longer-term benefits [13][14].

港股一日游，集体小幅低开后全天震荡反弹，但始终被中轴压制，恒生科技低开低走跌幅居前，恒生内房地、恒生工商等紧随其后，恒生金融指 数和恒生内石油逆势收涨。 | 名称 | 现价 | 涨幅1 | 涨跌 | 开盤 | 昨收 | 最高 | 最低 | 成交额 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 恒生科技指数 | 3468.50 | -1.14% | -40.11 | 3451.18 | 3508.61 | 3474.96 | 3435.28 | 213.8亿 | | 恒指波幅指数 | 19.09 | -0.73% | -0.14 | 19.36 | 19.23 | 19.42 | 18.83 | 0 | | 恒生内地房地 | 1029.26 | -0.61% | -6.33 | 1030.93 | 1035.59 | 1031.90 | 1012.78 | 9.041亿 | | 恒生工商指数 | 9701.92 | -0.49% | -47.56 | 9664.10 | 9749.48 | 9716.73 | 9640.23 | 280. ...

Group 1 - The Hang Seng Index maintained a slight increase of 0.17% at the close, with sectors such as internet, technology, healthcare, and banking showing minor gains, while the consumer sector experienced a decline [1] - The Hang Seng Technology Index saw a narrow range of fluctuations, closing up 0.14%, with notable increases in stocks like SMIC (up 3.14%), BYD, Kuaishou, NetEase, and Tencent, while Alibaba and Baidu faced slight declines [3] - The Hang Seng Healthcare Index rebounded after a previous drop, closing up 0.13%, with stocks like JD Health, WuXi Biologics, and Innovent Biologics showing small gains, whereas companies like 3SBio, CSPC Pharmaceutical, and Hansoh Pharmaceutical remained weak [3] Group 2 - The consumer sector faced a downturn, closing down 0.3%, with significant declines in stocks such as WuXi AppTec (down 3.22%) and Lao Pu Gold (down 2.67%), while companies like China Resources Beer, Horizon Robotics, and Alibaba Health managed to rise against the trend [3]

Group 1 - The Hong Kong Innovative Drug ETF (159567) closed down 0.26% with a trading volume of 221 million yuan on December 26 [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of December 25, 2024, the fund's latest share count was 10.467 billion shares, with a total size of 8.204 billion yuan, reflecting a year-to-date increase of 2547.36% in shares and 2071.41% in size [1] Group 2 - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 56.94% during the management period [2] - The top holdings of the fund include companies such as BeiGene, CanSino Biologics, Innovent Biologics, and others, with significant weightings in the portfolio [2] - The largest holding is BeiGene, accounting for 10.62% of the portfolio, followed by CanSino Biologics at 10.55% and Innovent Biologics at 10.21% [2]

Core Insights - The article reflects on the evolution of the "Hurun Rich List" over 25 years, highlighting the transformation of wealth perception and the changing landscape of China's economy [2][3][12]. Group 1: Historical Context - In 1999, the first "Hurun Rich List" was created, featuring 50 individuals, with the founder of CITIC Group, Rong Yiren, ranked first [2][3]. - The list initially faced skepticism and fear among entrepreneurs, as many listed individuals later faced legal troubles, leading to the term "killing pig list" being used to describe it [5][6][9]. Group 2: Changes in Wealth Dynamics - By 2025, the list expanded to 1,434 individuals, with the threshold for inclusion set at 5 billion RMB, indicating significant growth in China's private economy [3][13]. - The composition of the list has shifted dramatically, with real estate moguls dominating in the early years, but by 2025, only one real estate entrepreneur, Wu Yajun, remains in the top 100 [20][21][24]. Group 3: Emerging Industries - The industrial products sector now leads the list with 16.5% representation, followed by consumer goods and life sciences, reflecting a shift in wealth creation from real estate to technology and innovation [24][25]. - Notable figures in 2025 include Zhong Shanshan, Zhang Yiming, and Ma Huateng, with wealth derived from sectors like bottled water, technology, and pharmaceuticals [25][26]. Group 4: Globalization and New Generations - The article discusses the new generation of entrepreneurs who are inherently globalized, with many starting their businesses with a global market focus, unlike previous generations [36]. - The transition of leadership to the next generation is highlighted, with examples of heirs taking over large enterprises, indicating a potential for continuity in business values and networks [37][39]. Group 5: Cultural Shifts - There is a notable cultural shift among Chinese entrepreneurs, with a growing emphasis on education and networking, as many pursue advanced degrees even after achieving success [28][30]. - The article emphasizes the importance of transparency in wealth, with Hu Run advocating for wealth to be openly discussed and legally recorded as a sign of a mature business society [12][26].

恒生医疗高开低走后逆势大跌0.65%，其中三生制药下跌1.37%，石药集团下跌1.24%，翰森制药、药明 生物、康方生物等股均小幅收跌；京东健康、药明康德、信达生物等股逆势小跌。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ 恒生科技冲高回落后全天维持在中轴上方盘整，截至收盘上涨0.14%。其中中芯国际大涨3.12%，比亚 迪股份、快手、网易、腾讯控股等股均小幅收涨；阿里巴巴、百度集团等股小幅收跌。 银行止跌企稳，截至收盘小涨0.09%，其中汇丰控股上涨1.23%，郑州银行、重庆农村商业银行、邮储 银行、大新银行、渣打银行等股均小幅收涨；青岛银行、光大银行、中信银行等股逆势收跌。 恒生指数全天维持在中轴上方窄幅盘整，截至收盘小涨0.17%。恒生科技和银行小幅收涨；大消费、恒 生医疗、互联网等逆势收跌。 ...